Autologous Blood Treatment for Ocular Surface Disease

Status Completed

Clinical Trial Summary

In this study, we aim to determine the efficacy of autologous blood as an alternative to autologous serum eye drops (ASE) in people with severe dry eyes and ocular surface inflammation. ASE are drops manufactured from the patient's own blood. Perceived benefits are that human blood contains multiple components that are beneficial to healing and maintaining a healthy ocular surface, including epidermal growth factor, and transforming growth factor β, in addition to fibronectin, vitamin A, and various growth factors. We wish to assess whether administering autologous blood directly to their eye would also be an effective treatment in the management of severe dry eye. It will be the first study analysing the potential benefits of this relatively novel treatment in Scotland and will consider its role in treating an important debilitating condition.

Clinical Trial Description

The surface of the eye, including the cornea, is dependent on the tear film to protect it. An adequate tear film prevents epithelial breakdown, ulceration and secondary infection. The continual regeneration of the corneal epithelium is supported by various components that reside in human tears, such as growth factors, vitamins, electrolytes and neuropeptides. There are various ocular conditions that can lead to a deficiency in any of these tear constituents and can result in excessive surface dryness. This can lead to corneal surface breakdown, non-healing ulceration, secondary infection, globe perforation and sight loss, in addition to severe pain for patients, all of which can have a significant negative impact on a patient's quality of life. First line therapy in the treatment of tear deficiency is in the form of ocular lubricants. Multiple formulations are available in drop, gel and ointment form. Lubricants act as barriers in one form or another to protect the epithelial surface from mechanical trauma. However, in the presence of an unhealthy tear film or corneal epithelial surface, barrier protection alone is inadequate to promote surface regeneration and wound healing. Therefore, even the use of frequent and continual ocular lubricants may be of no benefit to patients with severe ocular surface disease (OSD). In this study, we aim to determine the efficacy of autologous blood as an alternative to autologous serum eye drops (ASE) in people with severe dry eyes and ocular surface inflammation. ASE are drops manufactured from the patient's own blood. Perceived benefits are that human blood contains multiple components that are beneficial to healing and maintaining a healthy ocular surface, including epidermal growth factor, and transforming growth factor β, in addition to fibronectin, vitamin A, and various growth factors. We wish to assess whether administering autologous blood directly to their eye would also be an effective treatment in the management of severe dry eye. It will be the first study analysing the potential benefits of this relatively novel treatment in Scotland and will consider its role in treating an important debilitating condition. ;

Study Design

Related Conditions & MeSH terms

Ocular Surface Disease

Clinical Trial Details

NCT number	NCT03659955
Study type	Interventional
Source	NHS Lanarkshire
Contact
Status	Completed
Phase	N/A
Start date	November 7, 2017
Completion date	March 14, 2019

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT04067973` - Impact of Prematurity on the Optic Nerve
Completed	`NCT04828057` - Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting
Not yet recruiting	`NCT06375343` - Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive®	Phase 1
Completed	`NCT00346450` - Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Transplantation	Phase 3
Completed	`NCT04351100` - Efficacy of Diacerein on Ocular Surface Disease in Degenerative Arthritis Patients
Completed	`NCT04536129` - Effects of Topical Low Dose Preservative-free Hydrocortisone on Intraocular Pressure	N/A
Completed	`NCT01254370` - Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to Treat Glaucoma and Ocular Surface Disease	Phase 2
Completed	`NCT00554411` - Assessing Ocular Surface Changes After Changing Glaucoma Medications	N/A
Completed	`NCT03769454` - A Phase I Study of PP-001 Eye Drops in Healthy Adult Volunteers	Phase 1
Recruiting	`NCT06256770` - Evaluation of the Safety and Efficacy of Rigid Breathable Scleral Contact Lenses for the Correction of Ametropia
Completed	`NCT04673604` - From Preserved, to Preservative-free Cyclosporine 0.1% Enhanced Triple Glaucoma Therapy	N/A
Not yet recruiting	`NCT06370585` - Clinical Study to Evaluate the Safety and Tolerability of PRO-229 Ophthalmic Solution Compared to Lagricel® Ofteno PF	Phase 1
Withdrawn	`NCT04735510` - Novel Use of Restasis and PROSE Devices	Phase 3
Suspended	`NCT00348114` - Transplantation of Cultivated Limbal Epithelium on Amniotic Membrane for Limbal Stem Cell Deficiency	Phase 2
Recruiting	`NCT04010422` - Ocular Function in Autism Spectrum Disorder
Completed	`NCT05528016` - Short and Long-term Results of Skin Versus Skin Plus Orbicularis Resection Blepharoplasty	N/A
Completed	`NCT04452279` - Ocular Surface Disease Changes After iStent or iStent Inject Implantation With Phacoemulsification	N/A
Completed	`NCT04535388` - LK Scleral Lens for Patients With Intractable Ocular Surface Diseases	N/A
Recruiting	`NCT06298890` - The Pattern of Dry Eye Disease After Cataract Surgery
Completed	`NCT02802137` - 24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy	Phase 4